You are leaving bbraun.com.au . This link is provided strictly for information sharing purposes. B. Braun assumes no responsibility for the quality, content, nature, or reliability of any linked site.
Clinical impact of drug coated balloon-based percutaneous coronary intervention in patients with multivessel coronary artery disease
Significantly lower MACE rate in patients treated with SeQuent® Please (NEO) compared to DES Shin ES et al. JACC Cardiovasc Interv. 2023;16(3):292-299
Overview
Observational registry:
DCB (study device = SeQuent Please® (NEO)) in patients with MVD (2 or more coronary lesions)
Propensity score matched to patients receiving DES
Primary endpoint:
MACE @24 months (cardiac death, MI, TVR, stroke, stent thrombosis and major bleeding)
Results
In DCB-group 34.3 % of patients were treated with DCB-only, 65.7 % with hybrid PCI (DES+DCB)
Stent-length was significantly reduced by 63.7 % in DCB-group
MACE after 24 months was significantly lower in DCB-group vs. DES (3.9 % vs. 11 %; p=0.002)
Total population:
508 patients
DCB-Based
(n=254)
DES-only
(n=254)
p-value
Clinical endpoint after 24 months
MACE
3.9 % (10)
11.0 % (28)
0.002
Cardiac death
0.4 % (1)
2.4 % (6)
0.047
MI
0
1.2 % (3)
0.082
Stroke
0
0.4 % (1)
0.313
ST (definite/probable)
0
0.4 % (1)
0.333
TVR
3.1 % (8)
6.3 % (16)
0.095
Major bleeding
0.4 % (1)
2.8 % (7)
0.027
Conclusion
The DCB-based treatment approach showed a significantly reduced stent burden in multivessel PCI and this led to a significantly lower rate of MACE than the DES-only treatment.
